ARTICLE | Product Development

Eureka tackles major challenges for T cells in solid tumors with $45M E round, Lyell deal

Eureka is moving its TCR-mimicking antibodies forward with a new partner and new funding

March 17, 2020 10:44 PM UTC
Updated on Mar 21, 2020 at 1:53 AM UTC

Eureka is taking the next steps to bring cell therapies into solid tumors with a $45 million series E round and a new partnership with solid tumor cell therapy company Lyell.

Eureka Therapeutics Inc. and Lyell Immunopharma Inc., which led the venture round, are teaming up to develop T cell therapies against several solid tumor targets; details are undisclosed. ...

Access The Full Article